Lung cancer

COCOON

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.
  • Open at Paris since : 24/04/2024
  • Target : Adult
  • Phase : Phase II

Trial description

The primary objective is to evaluate whether enhanced dermatologic management can reduce the incidence;of Grade =2 DAEIs by Week 12 when compared with standard-of-care skin management in participants;with locally advanced or metastatic Stage IIIB/C-IV EGFR-mutated NSCLC treated first-line with;amivantamab and lazertinib. The key secondary objectives are to further characterize dermatologic toxicity;and the impact on participantsÀ quality oflife.
Url of the trial

Main investigator